Retina International welcomes EMA’s approval of voretigene neparvovec (Luxturna), a gene therapy for the treatment of LCA, in Europe
What We Do
For almost 40 years, Retina International (RI) has been the voice of patient-led voluntary groups, charities and foundations world wide who fund and support Retinal Research that is seeking a cure for Retinitis Pigmentosa (RP), Macular Degeneration, Ushers Syndrome & Allied Retinal Dystrophies.
Inherited Retinal Disease Toolkit
An educational resource designed for patients with IRDs, their representatives and their healthcare professionals to address the challenges of vision health and blindness.
